Latest news with #Redox
Irish Examiner
2 days ago
- Sport
- Irish Examiner
Into the west: Niamh Mallon at home with Galway after year of 'overthinking'
Mallon in maroon. A more comfortable fit than last year. On-field contributions are better for that improved fit. It's amazing what stirs unseen beneath the surface. Niamh Mallon made her Galway debut 45 minutes into last year's Camogie League final. She rose three white flags in the quarter of an hour she was on the field. Her debut campaign in adopted colours concluded with All-Star selection at right corner-forward. It was a selection heavily influenced by an All-Ireland semi-final display where she top-scored with 1-3 from play and won the 59th minute free that triggered their decisive late scoring burst. A seamless switch into new colours and new environs. Well, to those on the outside looking in anyway. After her latest semi-final heroics on Saturday, the Portaferry native opened up on a difficult maiden voyage in maroon. A sports scientist at Galway-based firm Orreco, where she conducts the company's Redox testing, essentially a point-of-care blood test for oxidated stress levels, Mallon commuted from Galway to continue lining out for Down following her move west in 2018. The commuting ceased last year. She took on the challenge of trying to make the cut in one of the most competitive camogie dressing-rooms around. That challenge was quickly conquered. The challenge that stumped her was she herself feeling comfortable in maroon. 'Last year was a huge challenge,' she began. 'It probably was quite stressful from my own perspective, a new environment, something I wasn't used to in 12, 13 years in terms of a camogie dressing-room. I have definitely got more comfortable around the group, I have definitely got more comfortable around the environment, and that is leading to a lot more enjoyment. I couldn't be happier, to be honest with you.' The western welcome was there from the first moment she joined Cathal Murray's group. The issue was Mallon convincing herself she belonged. That took time. 'It was completely my own doing. It was nobody else. Cathal and the girls were super, and they did everything in their power to integrate me into the group. But it was something new to me and something I grappled with, and probably overthought a lot, whereas this year, I am completely comfortable in the group and it has led to a more enjoyable experience.' It has also led to a series of outstanding showings. For the second semi-final running, Mallon was Galway's top-scorer from play, albeit she shared the title on this occasion with Ailish O'Reilly. Along with her 1-2 tally, she won the Tipperary puckout for Galway's sixth point, was fouled for their first score after half-time, and had the assist for Aoife Donohue's final quarter white flag. With 1-17 across five games, she heads into the decider as their leading contributor from play. 'Last year was about finding my feet and probably me feeling the need to deliver, whereas this year I feel completely at ease and yeah, it has led to better performances and a more enjoyable experience overall,' continued Mallon, who serves as the nutritionist to Pádraic Joyce's Galway footballers. The Down sharpshooter was one of seven starters from Saturday's team that didn't feature in the 2023 semi-final defeat to Cork. Last year, so, was about returning to the final. This year is about traveling the whole distance. 'Today was definitely a stepping stone on what we want to do. Last year, there was huge euphoria and joy after the semi-final, such was the nature of how we won the game, whereas today, it felt like we had a job to do, and we did it. We are just delighted to be heading back to Croke Park in two weeks' time. That was ultimately the goal. 'I think the team as a whole has matured massively over the past 12 months. Last year, Ciara Hickey and Olwen Rabbitte probably hadn't been involved in games like this, whereas now, a year under the belt, 12 months of training, 12 months of being used to the players around them, the environment, they have huge aspirations and ambitions of getting back to the biggest day. That probably all contributed to the performance today. 'Cathal has done a brilliant job of bleeding players into the group over the last 12-18 months, myself included. It has been hugely important. We are in the final, but we have a lot of work to do if we are going to pull it off.' Mallon was held to a point in the '24 decider defeat to Cork. Now more at ease in maroon, the Galway import is striving for improved final involvement.
Yahoo
22-06-2025
- Business
- Yahoo
Owning 63% in Redox Limited (ASX:RDX) means that insiders are heavily invested in the company's future
Insiders appear to have a vested interest in Redox's growth, as seen by their sizeable ownership The top 7 shareholders own 53% of the company 13% of Redox is held by Institutions We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. If you want to know who really controls Redox Limited (ASX:RDX), then you'll have to look at the makeup of its share registry. With 63% stake, individual insiders possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). So, insiders of Redox have a lot at stake and every decision they make on the company's future is important to them from a financial point of view. In the chart below, we zoom in on the different ownership groups of Redox. See our latest analysis for Redox Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. We can see that Redox does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Redox, (below). Of course, keep in mind that there are other factors to consider, too. Redox is not owned by hedge funds. Our data suggests that Richard Coneliano, who is also the company's Chief Operating Officer, holds the most number of shares at 15%. When an insider holds a sizeable amount of a company's stock, investors consider it as a positive sign because it suggests that insiders are willing to have their wealth tied up in the future of the company. Robert Coneliano is the second largest shareholder owning 10% of common stock, and Claudia Walters holds about 8.0% of the company stock. Furthermore, CEO Raimond Coneliano is the owner of 2.5% of the company's shares. We did some more digging and found that 7 of the top shareholders account for roughly 53% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. It seems that insiders own more than half the Redox Limited stock. This gives them a lot of power. So they have a AU$675m stake in this AU$1.1b business. Most would argue this is a positive, showing strong alignment with shareholders. You can click here to see if those insiders have been buying or selling. With a 24% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Redox. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run. While it is well worth considering the different groups that own a company, there are other factors that are even more important. For example, we've discovered 1 warning sign for Redox that you should be aware of before investing here. Ultimately the future is most important. You can access this free report on analyst forecasts for the company. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. — Investing narratives with Fair Values Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges By Robbo – Community Contributor Fair Value Estimated: A$2.42 · 0.1% Overvalued Vossloh rides a €500 billion wave to boost growth and earnings in the next decade By Chris1 – Community Contributor Fair Value Estimated: €78.41 · 0.1% Overvalued Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth By Unike – Community Contributor Fair Value Estimated: $325.55 · 0.6% Undervalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
26-05-2025
- Business
- Yahoo
Here's What's Concerning About Redox's (ASX:RDX) Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. In a perfect world, we'd like to see a company investing more capital into its business and ideally the returns earned from that capital are also increasing. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. So while Redox (ASX:RDX) has a high ROCE right now, lets see what we can decipher from how returns are changing. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. The formula for this calculation on Redox is: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.21 = AU$117m ÷ (AU$736m - AU$167m) (Based on the trailing twelve months to December 2024). Thus, Redox has an ROCE of 21%. In absolute terms that's a great return and it's even better than the Trade Distributors industry average of 12%. View our latest analysis for Redox In the above chart we have measured Redox's prior ROCE against its prior performance, but the future is arguably more important. If you're interested, you can view the analysts predictions in our free analyst report for Redox . On the surface, the trend of ROCE at Redox doesn't inspire confidence. To be more specific, while the ROCE is still high, it's fallen from 33% where it was five years ago. Meanwhile, the business is utilizing more capital but this hasn't moved the needle much in terms of sales in the past 12 months, so this could reflect longer term investments. It's worth keeping an eye on the company's earnings from here on to see if these investments do end up contributing to the bottom line. On a related note, Redox has decreased its current liabilities to 23% of total assets. That could partly explain why the ROCE has dropped. What's more, this can reduce some aspects of risk to the business because now the company's suppliers or short-term creditors are funding less of its operations. Since the business is basically funding more of its operations with it's own money, you could argue this has made the business less efficient at generating ROCE. In summary, Redox is reinvesting funds back into the business for growth but unfortunately it looks like sales haven't increased much just yet. Unsurprisingly then, the total return to shareholders over the last year has been flat. On the whole, we aren't too inspired by the underlying trends and we think there may be better chances of finding a multi-bagger elsewhere. Like most companies, Redox does come with some risks, and we've found 1 warning sign that you should be aware of. If you'd like to see other companies earning high returns, check out our free list of companies earning high returns with solid balance sheets here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
13-05-2025
- Health
- Yahoo
Creyos Partners with Redox to Eliminate Barriers to Cognitive Health Data in EHRs
Partnership redefines how health systems bring cognitive screening into routine care at scale TORONTO, May 13, 2025 /PRNewswire/ -- Creyos, the leading online platform for objective cognitive and behavioral health assessments, today announced its partnership with Redox, a leading provider of healthcare data interoperability solutions. This strategic collaboration enables large health systems and integrated delivery networks to seamlessly embed Creyos' cognitive testing into their electronic health records (EHRs), eliminating one of the biggest barriers to scaling proactive brain health care. This partnership comes at a time when cognitive and behavioral health assessments are becoming essential to high-quality, preventive care. Over 55 million people worldwide are currently living with dementia, and that number is projected to reach 139 million by 2050. Early and accurate screening is critical for enabling timely intervention, personalized care planning, and improved outcomes. As health systems shift toward value-based care, Creyos is helping providers make cognitive health a core part of routine care. Its tools are clinically proven and easy to implement. Most technology fails to gain traction in large health systems due to poor alignment with clinical workflows. Creyos overcomes this by leveraging Redox's expansive EHR network to deliver seamless data integration and platform access. Its scientifically validated dementia screening and assessments are now available at the point of care, right when providers need them. "We're at a turning point in how health systems approach cognitive health," said Marc Lipton, CEO of Creyos. "To deliver on the promise of value-based care, we need tools that don't just work clinically but also work operationally. This partnership with Redox eliminates the workflow and integration barriers that have slowed adoption for years. It puts Creyos assessments exactly where they need to be, within the systems clinicians already use." Redox's platform supports interoperability across more than 90 EHR systems including, Cerner, eClinicalWorks, and Allscripts, among many others. Health systems deploying Creyos through this partnership can automatically deliver cognitive assessments and patient results to their EHRs without complex, time-consuming IT work. This ensures: Timely Decision-Making: Providers receive screener and assessment data directly in their existing systems, allowing for faster clinical decision making, interventions, and coordinated care planning. Improved Clinical Workflow Efficiency: Automating the integration of cognitive test results reduces administrative burdens, giving providers more time to focus on patient care. Scalability for Large Health Systems: Whether supporting one location or a national network of clinics, the Creyos-Redox integration is highly scalable and adaptable to the unique needs of any enterprise system. Early Detection and Proactive Care: Cognitive health is a critical component of preventive care, especially in aging populations and for at-risk patient groups. By integrating Creyos' cognitive and behavioral assessments directly into EHRs, providers can monitor cognitive decline over time, ensuring they catch early warning signs of conditions such as dementia or mild cognitive impairment (MCI) before they worsen. "Creyos is bringing cognitive health into everyday clinical workflows, and we're proud to power that shift," said Trip Hofer, CEO of Redox. "When results from tools like this are embedded directly into EHR systems, providers can act sooner, and patients benefit from more timely, connected care. This is exactly the kind of integration we believe healthcare needs more of." Creyos EHR integration through Redox is now available for all Creyos customers. Health systems interested in getting Creyos for their practice can learn more by visiting About CreyosCreyos, formerly known as Cambridge Brain Sciences, is a pioneering healthcare technology company dedicated to transforming how healthcare providers assess and manage patient brain health. Supporting clinicians and health systems worldwide, the Creyos platform includes objective online tasks, digital behavioral health screeners, and condition-specific assessments that deliver actionable insights, promote early intervention, and enable evidence-based clinical decisions for various cognitive and behavioral health conditions, including dementia, ADHD, depression, anxiety, and others. Backed by 30 years of research and a normative database of over 85,000 participants, the FDA-registered Creyos platform has been published in over 400 peer reviewed studies and is recognized as a scientifically-validated solution for measuring and monitoring patient brain health. For more information about Creyos visit About RedoxRedox is your highway to better healthcare. We help providers, payers, digital health vendors/independent service providers, EHRs, and Life Sciences companies power better care with seamless data interoperability. Our secure platform's read/write capabilities translate, normalize, and enrich complex healthcare data in real time. With more than 9,600 live connections, organizations across North America use Redox technology to achieve faster speed to value across a wide range of systems, applications, and workflows. For more information, visit or follow us on LinkedIn and X. Media Contact: Erin SmithChief Marketing and Engagement Officer, Creyos(647)- View original content to download multimedia: SOURCE Creyos Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
06-05-2025
- Business
- Business Wire
IntelePeer and Redox Partner to Accelerate Implementation Timelines of AI Solutions for PE-backed Healthcare Companies
BUSINESS WIRE)--IntelePeer, the leading end-to-end conversational AI platform provider, and Redox, a leading provider of healthcare data interoperability solutions, today announce a new partnership to accelerate AI implementations for private equity-backed healthcare companies. Through this collaboration, healthcare groups using IntelePeer's SmartAgent and SmartOffice solutions can rely on the simplicity of a turnkey AI solution that can be rapidly deployed with secure access into hundreds of healthcare applications, including electronic health record (EHR) systems and Practice Management Solutions (PMS). Coupled with IntelePeer's reliable and scalable voice and omnichannel AI agents, these solutions enable organizations to achieve financial returns in less than three months. 'IntelePeer is deeply committed to helping private equity-backed healthcare organizations achieve tangible business results in less than 90 days,' said IntelePeer CEO, Frank Fawzi. 'By integrating Redox's industry-leading interoperability network with IntelePeer's AI-powered automation platform, we're eliminating one of the biggest pain points our healthcare customers face—connecting their communications systems within complex EHR and PMS environments. This integration allows providers to deploy communications solutions quickly and securely, all while maintaining compliance and improving business outcomes. It's a powerful step forward in enabling medical and dental practices to modernize operations, reduce administrative overhead, and rapidly deliver business results that increase revenue and improve net margins for their organizations.' Through the Redox partnership, IntelePeer is making it easy for healthcare organizations to streamline patient engagement, automate communications, and drive better outcomes through frictionless data exchange. Redox's secure and scalable platform allows IntelePeer to connect with more than 90 EHR systems, empowering organizations to: Increase revenue and drive greater efficiency and cost savings with improved appointment management, reduced no shows, and automated payment management. Improve care coordination by automating communications triggered by real-time EHR events. Reduce administrative burden with intelligent voice, SMS, and chatbot workflows that free up staff time. Enhance patient satisfaction and outcomes by meeting patients where they are with timely and relevant information. 'With Redox's real-time, bi-directional data exchange, IntelePeer customers can deliver personalized and connected experiences at the right time to improve patient care management and drive greater operational efficiencies,' said Rachel Witalec, Chief Product Officer at Redox. 'Dealing with disparate legacy data from multiple source formats is complex. Redox simplifies the process, delivering the necessary data in real-time to automate workflows and bring use cases to life, all while increasing in-office productivity.' IntelePeer's SmartAgent solution automates inbound interactions for medical practices and dental offices, helping them quickly and easily streamline front office responsibilities and empower self-service communications for a much faster ROI. It allows dental providers to manage spikes in call capacity and engage patients with conversational AI appointment management and reminders. This reduces front office or contact center costs while optimizing schedules and revenues and adhering to strict compliance measures. SmartOffice offers multi-facility practices, unparalleled automation, and enhanced interaction resolution. It allows for routine patient interactions to be addressed without the need for human intervention, giving staff time back to focus on more complex patient needs. To learn more about IntelePeer, visit: About IntelePeer IntelePeer streamlines customer interactions, enabling businesses and contact centers to lower costs, improve the customer experience, and accelerate return on investment. Harnessing the power of agentic AI, IntelePeer's Conversational AI Platform delivers speed, observability, visibility, and flexibility — all built on top of a global, secure communications network. Producing human-like interactions, the platform automates voice and digital customer service capabilities and provides industry-leading time-to-value with solutions that work seamlessly with existing enterprise software and infrastructure, and easy-to-use tools that can be utilized by anyone.
